Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B6bcef10826a949e1d1f3e32a2c0a0f1d> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B6bcef10826a949e1d1f3e32a2c0a0f1d NCIT_P378 "NCI" @default.
- B6bcef10826a949e1d1f3e32a2c0a0f1d type Axiom @default.
- B6bcef10826a949e1d1f3e32a2c0a0f1d annotatedProperty IAO_0000115 @default.
- B6bcef10826a949e1d1f3e32a2c0a0f1d annotatedSource NCIT_C182005 @default.
- B6bcef10826a949e1d1f3e32a2c0a0f1d annotatedTarget "A human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2; VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon administration, pulocimab specifically binds to and inhibits VEGFR-2 on vascular endothelial cells, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types." @default.